Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether aerosolized vancomycin is effective in the treatment of methicillin-resistant staphylococcus aureus pneumonia under mechanical ventilation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Seoul National University Bundang Hospital
• Treatments: Methicillin; Vancomycin

Criteria

Inclusion Criteria:

• Nosocomial or severe community-acquired pneumonia due to Methicillin-Resistant Staphylococcus aureus

• Must be mechanically ventilated in intensive care unit

Exclusion Criteria:

• Non-bacterial pneumonia, such as viral, fungal, tuberculosis infections

• Underlying respiratory condition: bronchiectasis, post-tuberculosis, chronic obstructive pulmonary disease or asthma

• Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or drainage

• Already or previous treated with intravenous vancomycin (Not pneumonia)

• Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin

• Hypersensitivity of vancomycin or glycopeptide antibiotics

• Positive culture of Enterococcus in respiratory specimen

• Pregnant or Breast-feeding patient

• Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3 months, transplantation recipients, AIDS patients

• Another aerosolized antibiotics within 48 hours of study enrollment

• Not adherent to mechanical ventilation protocol of this study

• Not arterial line monitoring

• Vancomycin minimum inhibitory concentration >= 2㎍/㎖ of cultured Staphylococcus aureus